Patent ID: 8518890
Filing Date: 2013-08-27
Classification: A61K,A61P

Abstract:
1. A method for treating prostate cancer, which comprises administering an effective amount of an LHRH receptor agonist or antagonist or a salt thereof to a mammal in need thereof, and after a prostate cancer cell has become highly sensitive to androgen, administering an effective amount of an androgen receptor agonist or a salt thereof, wherein the LHRH receptor agonist is a peptide of the formula: wherein R the LHRH receptor antagonist is selected from the group consisting of abarelix, ganirelix, cetrorelix, 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-ethylureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, and 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-ethylureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione hydrochloride; and the androgen receptor agonist is a steroidal androgen receptor agonist selected from the group consisting of dehydroepiandrosterone, testosterone, dihydrotestosterone, androstenedione, Mestanolone, Oxymesterone, Methandrostenolone, Fluoxymesterone, Chlorotestosterone acetate, Methenolone acetate, Oxymetholone, Stanozolol, Furazabol, Oxandrolone, 19-Nortestosterone, Norethandrolone, Ethylestrenol and Norbolethone, or a salt thereof.